191 related articles for article (PubMed ID: 1374868)
1. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.
Mercer JG; Lawrence CB
Neurosci Lett; 1992 Mar; 137(2):229-31. PubMed ID: 1374868
[TBL] [Abstract][Full Text] [Related]
2. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
Corp ES; McQuade J; Moran TH; Smith GP
Brain Res; 1993 Sep; 623(1):161-6. PubMed ID: 8221086
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.
Hill DR; Woodruff GN
Brain Res; 1990 Sep; 526(2):276-83. PubMed ID: 2257485
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia.
Widdop RE; Krstew E; Mercer LD; Carlberg M; Beart PM; Jarrott B
J Auton Nerv Syst; 1994; 46(1-2):65-73. PubMed ID: 8120343
[TBL] [Abstract][Full Text] [Related]
5. Control of gallbladder contractions by cholecystokinin through cholecystokinin-A receptors in the vagal pathway and gallbladder in the dog.
Sonobe K; Sakai T; Satoh M; Haga N; Itoh Z
Regul Pept; 1995 Dec; 60(1):33-46. PubMed ID: 8747782
[TBL] [Abstract][Full Text] [Related]
6. "Gastrin" and "CCK" receptors on histamine- and somatostatin-containing cells from rabbit fundic mucosa-II. Characterization by means of selective antagonists (L-364,718 and L-365,260).
Roche S; Gusdinar T; Bali JP; Magous R
Biochem Pharmacol; 1991 Jul; 42(4):771-6. PubMed ID: 1714276
[TBL] [Abstract][Full Text] [Related]
7. Effect of neonatal capsaicin treatment on cholecystokinin-(CCK8) satiety and axonal transport of CCK binding sites in the rat vagus nerve.
Mercer JG; Farningham DA; Lawrence CB
Brain Res; 1992 Jan; 569(2):311-6. PubMed ID: 1371709
[TBL] [Abstract][Full Text] [Related]
8. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
[TBL] [Abstract][Full Text] [Related]
9. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
10. Pathways of Fos expression in locus ceruleus, dorsal vagal complex, and PVN in response to intestinal lipid.
Mönnikes H; Lauer G; Bauer C; Tebbe J; Zittel TT; Arnold R
Am J Physiol; 1997 Dec; 273(6):R2059-71. PubMed ID: 9435662
[TBL] [Abstract][Full Text] [Related]
11. Modulatory role for CCK-B antagonists in Parkinson's disease.
Boyce S; Rupniak NM; Tye S; Steventon MJ; Iversen SD
Clin Neuropharmacol; 1990 Aug; 13(4):339-47. PubMed ID: 1976438
[TBL] [Abstract][Full Text] [Related]
12. Response of the gastric vagal afferent activity to cholecystokinin in rats lacking type A cholecystokinin receptors.
Kurosawa M; Bucinskaite V; Taniguchi T; Miyasaka K; Funakoshi A; Lundeberg T
J Auton Nerv Syst; 1999 Jan; 75(1):51-9. PubMed ID: 9935269
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographical detection of cholecystokinin-A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329.
Hill DR; Shaw TM; Graham W; Woodruff GN
J Neurosci; 1990 Apr; 10(4):1070-81. PubMed ID: 2329368
[TBL] [Abstract][Full Text] [Related]
14. Effect of cholecystokinin receptor antagonists, MK-329 and L-365,260, on cholecystokinin-induced acid secretion and histidine decarboxylase activity in the rat.
Kawabata S; Kanayama S; Shinomura Y; Miyazaki Y; Imamura I; Moriwaki K; Wada H; Tarui S
Regul Pept; 1991 Jul; 35(1):1-10. PubMed ID: 1924892
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
16. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR
Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971
[TBL] [Abstract][Full Text] [Related]
17. Transport of cholecystokinin (CCK) binding sites in subdiaphragmatic vagal branches.
Moran TH; Smith GP; Hostetler AM; McHugh PR
Brain Res; 1987 Jul; 415(1):149-52. PubMed ID: 2441809
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
Sinha J; Kurup A; Paleti A; Gupta SP
Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
[TBL] [Abstract][Full Text] [Related]
19. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
Crawley JN
J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
[TBL] [Abstract][Full Text] [Related]
20. Receptor mediation of the stimulus properties of cholecystokinin.
Melton PM; Riley AL
Pharmacol Biochem Behav; 1994 May; 48(1):275-9. PubMed ID: 8029299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
